|
US7388079B2
(en)
*
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
|
BRPI0406647A
(pt)
|
2003-01-06 |
2005-12-06 |
Angiochem Inc |
Método para transportar um composto através da barreira sanguìnea do cérebro
|
|
US7485706B2
(en)
*
|
2003-07-30 |
2009-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Neurodegenerative protein aggregation inhibition methods and compounds
|
|
JP5436856B2
(ja)
|
2005-07-15 |
2014-03-05 |
アンジオケム インコーポレーティッド |
薬学的複合体における担体としてのアプロチニンポリペプチドの使用
|
|
US8124095B2
(en)
*
|
2005-10-07 |
2012-02-28 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of erythropoietin to the CNS
|
|
US8053569B2
(en)
*
|
2005-10-07 |
2011-11-08 |
Armagen Technologies, Inc. |
Nucleic acids encoding and methods of producing fusion proteins
|
|
US8741260B2
(en)
*
|
2005-10-07 |
2014-06-03 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of GDNF to the CNS
|
|
US7981417B2
(en)
*
|
2006-06-07 |
2011-07-19 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting anti-bodies
|
|
WO2008022349A2
(en)
|
2006-08-18 |
2008-02-21 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
|
US20080200441A1
(en)
*
|
2007-02-14 |
2008-08-21 |
University Of Southern California |
Estrogen receptor modulators associated pharmaceutical compositions and methods of use
|
|
WO2008137066A1
(en)
*
|
2007-05-02 |
2008-11-13 |
The Board Of Regents Of The University Of Oklahoma |
Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
|
|
US9365634B2
(en)
|
2007-05-29 |
2016-06-14 |
Angiochem Inc. |
Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
|
|
US20100197012A1
(en)
*
|
2007-06-05 |
2010-08-05 |
National Tsing Hua University |
Application of RNA Interference Targeting dhfr Gene, to Cell for Producing Secretory Protein
|
|
AU2008282496B2
(en)
|
2007-07-27 |
2013-04-04 |
Armagen Technologies, Inc. |
Methods and compositions for increasing alpha-iduronidase activity in the CNS
|
|
TR201905480T4
(tr)
|
2008-04-18 |
2019-05-21 |
Angiochem Inc |
Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri.
|
|
MX2011004019A
(es)
|
2008-10-15 |
2011-06-24 |
Angiochem Inc |
Conjugados de etoposido y doxorubicina para entrega de farmacos.
|
|
BRPI0920209A2
(pt)
|
2008-10-15 |
2015-12-22 |
Angiochem Inc |
conjugados de agonistas de glp-1 e usos dos mesmos
|
|
CA2745524C
(en)
|
2008-12-05 |
2020-06-09 |
Angiochem Inc. |
Conjugates of neurotensin or neurotensin analogs and uses thereof
|
|
WO2010069074A1
(en)
|
2008-12-17 |
2010-06-24 |
Universite Du Quebec A Montreal |
Membrane type-1 matrix metalloprotein inhibitors and uses thereof
|
|
CA2748889A1
(en)
*
|
2009-03-18 |
2010-09-23 |
Armagen Technologies, Inc. |
Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
|
|
JP5616428B2
(ja)
|
2009-04-07 |
2014-10-29 |
ロシュ グリクアート アクチェンゲゼルシャフト |
三価の二重特異性抗体
|
|
WO2010121379A1
(en)
|
2009-04-20 |
2010-10-28 |
Angiochem Inc |
Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
|
|
WO2010142035A1
(en)
*
|
2009-06-11 |
2010-12-16 |
Angiochem Inc. |
Fusion proteins for delivery of gdnf and bdnf to the central nervous system
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
AU2010268726A1
(en)
|
2009-07-02 |
2012-01-19 |
Angiochem Inc. |
Multimeric peptide conjugates and uses thereof
|
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
|
EA025367B1
(ru)
|
2009-08-17 |
2016-12-30 |
Тракон Фармасьютикалз, Инк. |
Комбинированная терапия рака с помощью антител против эндоглина и агентов против vegf
|
|
JP2013507131A
(ja)
|
2009-10-09 |
2013-03-04 |
アーメイゲン・テクノロジーズ・インコーポレイテッド |
Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
|
|
US20130079382A1
(en)
|
2009-10-12 |
2013-03-28 |
Larry J. Smith |
Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
|
|
SI2575846T1
(sl)
*
|
2010-05-27 |
2015-09-30 |
Janssen Biotech, Inc. |
Peptidi, ki vežejo receptor za inzulinu podoben rastni faktor 1
|
|
WO2012021818A2
(en)
*
|
2010-08-13 |
2012-02-16 |
Georgetown University |
Ggf2 and methods of use
|
|
AR084020A1
(es)
|
2010-11-30 |
2013-04-17 |
Genentech Inc |
Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos
|
|
US11214610B2
(en)
|
2010-12-01 |
2022-01-04 |
H. Lundbeck A/S |
High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
|
|
US9884909B2
(en)
|
2010-12-01 |
2018-02-06 |
Alderbio Holdings Llc |
Anti-NGF compositions and use thereof
|
|
US9078878B2
(en)
|
2010-12-01 |
2015-07-14 |
Alderbio Holdings Llc |
Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
|
|
US9067988B2
(en)
|
2010-12-01 |
2015-06-30 |
Alderbio Holdings Llc |
Methods of preventing or treating pain using anti-NGF antibodies
|
|
JP6190723B2
(ja)
|
2010-12-01 |
2017-08-30 |
アルダーバイオ ホールディングス エルエルシー |
抗ｎｇｆ組成物およびその使用
|
|
US9539324B2
(en)
|
2010-12-01 |
2017-01-10 |
Alderbio Holdings, Llc |
Methods of preventing inflammation and treating pain using anti-NGF compositions
|
|
WO2012116926A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Antigen binding proteins
|
|
JP5768147B2
(ja)
|
2011-02-28 |
2015-08-26 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
一価抗原結合タンパク質
|
|
EP2709670A4
(en)
*
|
2011-05-18 |
2015-01-21 |
Childrens Hosp Medical Center |
TARGETED TRANSFER OF PROTEINS OVER THE BLOOD BRAIN BARRIER
|
|
DK2758076T3
(en)
*
|
2011-09-24 |
2019-04-01 |
Csl Behring Gmbh |
COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
|
|
AU2012346448B2
(en)
|
2011-12-02 |
2017-09-14 |
Armagen, Inc. |
Methods and compositions for increasing arylsulfatase A activity in the CNS
|
|
AU2013266611B2
(en)
*
|
2012-05-21 |
2016-08-11 |
Genentech, Inc. |
Methods for improving safety of blood-brain barrier transport
|
|
US9790264B2
(en)
|
2012-06-25 |
2017-10-17 |
The Brigham And Women's Hospital, Inc. |
Compounds and methods for modulating pharmacokinetics
|
|
EP2864360B1
(en)
|
2012-06-25 |
2017-09-06 |
The Brigham and Women's Hospital, Inc. |
Targeted therapeutics
|
|
EP2885318A4
(en)
|
2012-08-14 |
2016-03-30 |
Angiochem Inc |
PEPTIDE DENDRIMER CONJUGATES AND ITS USES
|
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
|
US9657098B2
(en)
|
2013-03-15 |
2017-05-23 |
Intrinsic Lifesciences, Llc |
Anti-hepcidin antibodies and uses thereof
|
|
WO2014189973A2
(en)
*
|
2013-05-20 |
2014-11-27 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
WO2015009961A1
(en)
|
2013-07-19 |
2015-01-22 |
Armagen Technologies, Inc. |
Compositions and methods related to structures that cross the blood brain barrier
|
|
US20150093399A1
(en)
|
2013-08-28 |
2015-04-02 |
Bioasis Technologies, Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
|
JP6618912B2
(ja)
|
2013-12-20 |
2019-12-11 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
改良された、組換えポリペプチド作製方法
|
|
WO2015091130A1
(en)
*
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Method for improving the recombinant production of soluble fusion polypeptides
|
|
CA2932547C
(en)
*
|
2014-01-06 |
2023-05-23 |
F. Hoffmann-La Roche Ag |
Monovalent blood brain barrier shuttle modules
|
|
AU2015321462B2
(en)
|
2014-09-22 |
2020-04-30 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
|
AU2015346444A1
(en)
|
2014-11-12 |
2017-05-04 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
|
DK3307326T3
(da)
|
2015-06-15 |
2020-10-19 |
Angiochem Inc |
Fremgangsmåder til behandling af leptomeningeal karcinomatose
|
|
MX391086B
(es)
|
2015-06-24 |
2025-03-21 |
Hoffmann La Roche |
Anticuerpos anti-receptor de transferrina con afinidad diseñada.
|
|
TWI769982B
(zh)
|
2015-06-24 |
2022-07-11 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之抗人類運鐵蛋白受體抗體
|
|
US11130815B2
(en)
|
2015-06-24 |
2021-09-28 |
Jcr Pharmaceuticals Co., Ltd. |
Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
NZ741067A
(en)
|
2015-10-02 |
2023-07-28 |
Hoffmann La Roche |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
|
US11752315B1
(en)
|
2016-10-07 |
2023-09-12 |
Carlos A. Hakim |
Method of treating normal pressure hydrocephalus
|
|
AU2017342555A1
(en)
|
2016-10-14 |
2019-05-30 |
Children's Medical Center Corporation |
Compositions and methods for treating diseases and disorders of the central nervous system
|
|
AU2017385274B2
(en)
|
2016-12-26 |
2024-02-22 |
Jcr Pharmaceuticals Co., Ltd. |
Fusion protein including BDNF
|
|
TWI761413B
(zh)
|
2016-12-26 |
2022-04-21 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
|
|
WO2018136434A1
(en)
|
2017-01-17 |
2018-07-26 |
Children's Medical Center Corporation |
Compositions and methods for diagnosing and treating peroxisomal diseases
|
|
CN108467428A
(zh)
*
|
2018-03-26 |
2018-08-31 |
江苏中新医药有限公司 |
一种清除rhNGF中N端截短及异常变异体的方法
|
|
PE20210111A1
(es)
*
|
2018-04-11 |
2021-01-19 |
Salubris Biotherapeutics Inc |
Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso
|
|
AU2019317460A1
(en)
*
|
2018-08-07 |
2021-03-18 |
Armagen, Inc. |
Methods and compositions for increasing the activity in the CNS of hexosaminidase a, acid sphingomyelinase, and palmitoyl-protein thioesterase 1
|
|
US12466865B2
(en)
|
2019-01-03 |
2025-11-11 |
The Board Of Trustees Of The University Of Illinois |
Method and kit for treating a neurodegenerative disease
|
|
PH12022550141A1
(en)
|
2019-07-19 |
2023-12-04 |
Oncoresponse Inc |
Immunomodulatory antibodies and methods of use thereof
|
|
CA3147701A1
(en)
|
2019-08-14 |
2021-02-18 |
Codiak Biosciences, Inc. |
Extracellular vesicles with antisense oligonucleotides targeting kras
|
|
CA3147366A1
(en)
|
2019-08-14 |
2021-02-18 |
Adam T. BOUTIN |
Extracellular vesicles with stat3-antisense oligonucleotides
|
|
KR20220070433A
(ko)
|
2019-08-14 |
2022-05-31 |
코디악 바이오사이언시즈, 인크. |
Stat6을 표적으로 하는 세포외 소포-aso 작제물
|
|
AU2020330133A1
(en)
|
2019-08-14 |
2022-03-17 |
Lonza Sales Ag |
Extracellular vesicle-ASO constructs targeting CEBP/beta
|
|
EP4013876A1
(en)
|
2019-08-14 |
2022-06-22 |
Codiak BioSciences, Inc. |
Extracellular vesicle-nlrp3 antagonist
|
|
EP4034247A1
(en)
|
2019-09-25 |
2022-08-03 |
Codiak BioSciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
|
WO2021184021A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting pmp22
|
|
WO2021184020A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Methods of treating neuroinflammation
|
|
WO2021248133A1
(en)
|
2020-06-05 |
2021-12-09 |
Codiak Biosciences, Inc. |
Anti-transferrin extracellular vesicles
|
|
EP3954393A1
(en)
|
2020-08-13 |
2022-02-16 |
Bioasis Technologies Inc. |
Combination therapies for delivery across the blood brain barrier
|
|
WO2022153957A1
(ja)
|
2021-01-12 |
2022-07-21 |
Ｊｃｒファーマ株式会社 |
リガンドと生理活性を有する蛋白質の融合蛋白質をコードする遺伝子が組み込まれた核酸分子
|
|
JP2024512236A
(ja)
|
2021-02-17 |
2024-03-19 |
ロンザ セールス アーゲー |
細胞外ベシクル－ｎｌｒｐ３アンタゴニスト
|
|
CN112851759B
(zh)
*
|
2021-02-23 |
2022-12-27 |
李婧炜 |
噬菌体展示技术筛选可穿越血-脑脊液屏障的多肽
|
|
MX2024005968A
(es)
|
2021-11-19 |
2024-08-06 |
Japan Chem Res |
Peptido que tiene afinidad por el receptor de transferrina humano.
|
|
TW202334428A
(zh)
|
2021-12-28 |
2023-09-01 |
日商Ｊｃｒ製藥股份有限公司 |
用於安全的基因治療之抗轉鐵蛋白受體抗體與具有生理活性的蛋白質之融合蛋白質
|
|
WO2024080305A1
(ja)
*
|
2022-10-11 |
2024-04-18 |
Ｊｃｒファーマ株式会社 |
血清アルブミンと生理活性を有する蛋白質との融合蛋白質
|
|
TW202436352A
(zh)
|
2023-02-07 |
2024-09-16 |
日商Ｊｃｒ製藥股份有限公司 |
人類運鐵蛋白受體親和性肽
|
|
AU2024325669A1
(en)
*
|
2023-08-14 |
2026-03-19 |
The Bionics Institute Of Australia |
A fusion protein
|